Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.1M Sell
18,845
-462
-2% -$102K 0.92% 36
2025
Q4
$4.41M Sell
19,307
-210
-1% -$47.8K 0.98% 30
2025
Q3
$4.52M Sell
19,517
-548
-3% -$112K 1.02% 28
2025
Q2
$3.72M Sell
20,065
-208
-1% -$38.7K 0.89% 33
2025
Q1
$4.25M Sell
20,273
-22
-0.1% -$4.28K 1.11% 27
2024
Q4
$3.61M Sell
20,295
-265
-1% -$48.7K 0.93% 34
2024
Q3
$4.06M Sell
20,560
-1,081
-5% -$202K 1.02% 30
2024
Q2
$3.71M Sell
21,641
-4,664
-18% -$773K 0.99% 34
2024
Q1
$4.79M Sell
26,305
-1,987
-7% -$342K 1.28% 21
2023
Q4
$4.38M Sell
28,292
-524
-2% -$76.4K 1.27% 22
2023
Q3
$4.3M Sell
28,816
-434
-1% -$63.7K 1.35% 20
2023
Q2
$3.94M Buy
29,250
+129
+0.4% +$18.9K 1.18% 21
2023
Q1
$4.64M Buy
29,121
+712
+3% +$109K 1.44% 19
2022
Q4
$4.59M Sell
28,409
-1,092
-4% -$167K 1.48% 16
2022
Q3
$3.96M Buy
29,501
+54
+0.2% +$7.75K 1.37% 16
2022
Q2
$4.51M Sell
29,447
-1,328
-4% -$203K 1.42% 16
2022
Q1
$4.99M Sell
30,775
-235
-0.8% -$34.1K 1.33% 18
2021
Q4
$4.2M Buy
31,010
+547
+2% +$64.6K 1.06% 26
2021
Q3
$3.29M Buy
30,463
+1,032
+4% +$118K 0.93% 31
2021
Q2
$3.31M Sell
29,431
-1,605
-5% -$181K 0.93% 32
2021
Q1
$3.36M Buy
31,036
+1,137
+4% +$122K 0.99% 31
2020
Q4
$3.2M Sell
29,899
-492
-2% -$47.3K 1% 33
2020
Q3
$2.66M Sell
30,391
-984
-3% -$92.6K 0.89% 40
2020
Q2
$3.08M Sell
31,375
-850
-3% -$74.8K 1.1% 24
2020
Q1
$2.46M Sell
32,225
-3,538
-10% -$301K 1.03% 26
2019
Q4
$3.17M Sell
35,763
-520
-1% -$43.2K 1.02% 26
2019
Q3
$2.75M Sell
36,283
-4,204
-10% -$288K 0.9% 30
2019
Q2
$2.94M Sell
40,487
-2,769
-6% -$218K 0.97% 28
2019
Q1
$3.49M Buy
43,256
+3,980
+10% +$326K 1.16% 22
2018
Q4
$3.62M Buy
39,276
+481
+1% +$42.3K 1.34% 17
2018
Q3
$3.67M Buy
38,795
+4,506
+13% +$427K 1.19% 22
2018
Q2
$3.18M Sell
34,289
-168
-0.5% -$16.4K 1.09% 24
2018
Q1
$3.26M Buy
34,457
+2,189
+7% +$240K 1.13% 22
2017
Q4
$3.12M Buy
+32,268
New +$3.04M 1.12% 26

Other funds holding ABBV

Plimoth Trust's ABBV Position: Q1 2026 in Review

Plimoth Trust reduced its AbbVie (ABBV) stake by 2.4% in Q1 2026, selling an estimated $102K and leaving 18,845 shares worth $4.1M. The position accounts for 0.92% of the portfolio, ranked #36.

Plimoth Trust first reported a position in ABBV in Q4 2017 and has held it in 34 quarters since. The position peaked at $4.99M in Q1 2022. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Plimoth Trust held 18,845 shares of AbbVie worth $4.1M as of Q1 2026.
  • Plimoth Trust sold 462 AbbVie shares in Q1 2026, an estimated $102K.
  • AbbVie made up 0.92% of Plimoth Trust's portfolio in Q1 2026, its #36 holding.
  • Plimoth Trust first reported a position in AbbVie in Q4 2017 and has held it in 34 quarters since.
  • Plimoth Trust's AbbVie position peaked at $4.99M in Q1 2022.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Plimoth Trust's 13F filing for Q1 2026, filed 27 Apr 2026.